Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.
AML is a type of cancer in which the bone marrow makes abnormal myeloblasts that build up in the bone marrow and blood, resulting in low or no production of normal blood cells (platelets, red blood cells, white blood cells)
MDS are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells
1. Blocking CD70-CD27 signaling, which leads to myeloid differentiation and stops proliferation of leukemic stem cells; and blocking release of soluble CD27, which is generated by CD70-CD27 ligation
2. Killing cells via Fc-dependent complement dependent cytotoxicity and enhanced antibody-dependent cellular cytotoxicity (ADCC)
Cusatuzumab is being developed under an exclusive global collaboration and license agreement with Janssen R&D and currently being investigated in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS).
For more info on clinical trials with cusatuzumab, please click the link below.